ProLectin-M,口服抗病毒药物,在印度一次小型试验期间,在住院的COVID-19病人中表现出快速的病毒检查和临床改善。 ProLectin-M, an oral antiviral, showed rapid viral clearance and clinical improvement in hospitalized COVID-19 patients during a small Indian trial.

Bioxytran Inc.宣布,在有轻度至中度COVID-19住院病人的口服抗病毒ProLectin-M上,第1b/2a阶段试验结果为积极结果。 Bioxytran, Inc. announced positive Phase 1b/2a trial results for its oral antiviral ProLectin-M in hospitalized patients with mild to moderate COVID-19. 在印度对39名参与者进行的一项研究中,最高剂量(16,800毫克/日)导致第5天前病毒检出时间大大提前,90%的病人显示没有可检测到的病毒,而安慰剂组(p=0.001)为20%。 In a study of 39 participants in India, the highest dose (16,800 mg/day) led to significantly earlier viral clearance by Day 5, with 90% of patients showing no detectable virus versus 20% in the placebo group (p=0.001). 到第5天,90%的高剂量患者在世卫组织常规比例表上取得了2点的改善。 A 2-point improvement on the WHO Ordinal Scale was seen in 90% of high-dose patients by Day 5. 到第7天,所有参与者在临床上都得到了改善。 All participants improved clinically by Day 7. ProLectin-M受到很好的容忍,没有发生严重的不利事件。 ProLectin-M was well tolerated with no serious adverse events. 该药物靶向半凝集素，即病毒进入细胞的宿主蛋白，暗示病毒具有对多种病毒的潜在作用。 The drug targets galectins, host proteins viruses use to enter cells, suggesting potential against multiple viruses. Bioxytran计划进行规模更大的试验,并正在进行美国和国际监管审查。 Bioxytran plans larger trials and is pursuing U.S. and international regulatory review.